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Hypomyelinating leukodystrophies (HMLs) are disorders involving aberrant myelin formation. The prototype of primary HMLs is the
X-linked Pelizaeus-Merzbacher disease (PMD) caused by mutations in PLP1. Recently, homozygous mutations in GJA12 encoding con-
nexin 47 were found in patients with autosomal-recessive Pelizaeus-Merzbacher-like disease (PMLD). However, many patients of both
genders with PMLD carry neither PLP1 nor GJA12 mutations. We report a consanguineous Israeli Bedouin kindred with clinical and
radiological ﬁndings compatible with PMLD, in which linkage to PLP1 and GJA12 was excluded. Using homozygosity mapping and
mutation analysis, we have identiﬁed a homozygous missense mutation (D29G) not previously described in HSPD1, encoding the mi-
tochondrial heat-shock protein 60 (Hsp60) in all affected individuals. The D29G mutation completely segregates with the disease-asso-
ciated phenotype. The pathogenic effect of D29G onHsp60-chaperonin activity was veriﬁed by an in vivo E. coli complementation assay,
which demonstrated compromised ability of the D29G-Hsp60mutant protein to support E. coli survival, especially at high temperatures.
The disorder, which we have termed MitCHAP-60 disease, can be distinguished from spastic paraplegia 13 (SPG13), another Hsp60-
associated autosomal-dominant neurodegenerative disorder, by its autosomal-recessive inheritance pattern, as well as by its early-onset,
profound cerebral involvement and lethality. Our ﬁndings suggest that Hsp60 defects can cause neurodegenerative pathologies of vary-
ing severity, not previously suspected on the basis of the SPG13 phenotype. These ﬁndings should help to clarify the important role of
Hsp60 in myelinogenesis and neurodegeneration.Introduction
Myelin formation is one of themajor processes involved in
normal brain development and maturation. Intact myeli-
nation of the central nervous system (CNS) results from
a highly controlled sequence of events requiring the coor-
dinated function of numerous genes. Inborn errors affect-
ing brain myelin are collectively recognized as leukodys-
trophies and can be classiﬁed into hypomyelinating
disorders, in which myelin is not properly formed, and de-
myelinating leukodystrophies in which myelin is initially
formed but is later destroyed.1 The prototype of early-onset
hypomyelinating leukodystrophy is Pelizaeus-Merzbacher
disease (PMD [MIM 312080]), an X-linked hypomyelinat-
ing disorder caused by mutations in the proteolipid pro-
tein 1 gene (PLP1) encoding lipophilin, the predominant
myelin protein present in the CNS.2,3 Approximately
80% of patients with typical PMD carry PLP1 mutations.4
Patients with the classical form of the disease are character-
ized by the appearance of nystagmus and psychomotor re-
tardation during the ﬁrst months of life and then muscle
hypotonia and progressive limb spasticity. Magnetic reso-30 The American Journal of Human Genetics 83, 30–42, July 2008nance imaging (MRI) of the brain in these patients typi-
cally shows diffuse hypomyelination.
Pelizaeus-Merzbacher-like disease (PMLD [MIM 608804
and MIM 260600]) is an autosomal-recessive disorder clin-
ically indistinguishable from PMD, in which PLP1 defects
are not found. Recently, mutations in GJA12 encoding
the gap junction protein connexin 47 (Cx47) have been
identiﬁed as causing PMLD.5,6 Nevertheless, according to
recent data, GJA12 defects account for less than 10% of
PMLD,7 and there are many patients of both genders
who suffer from PMLD, and who carry neither PLP1 nor
GJA12 mutations, suggesting the involvement of addi-
tional, as-yet-unidentiﬁed genetic defects that may also
cause perturbation of normal myelinogenesis.
Molecular chaperones, also known as heat-shock pro-
teins (HSPs), are highly conserved specialized proteins
that occur in all organisms and that play a crucial role in
cell maintenance and survival. Chaperones exert their bio-
logical effect by facilitating the correct folding of newly
synthesized or preexisting denatured proteins, thus
preventing the potential hazards of protein misfolding
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in protein folding, chaperones also function as regulators
of protein degradation, assist in protein targeting and
translocation across different cellular compartments, and
intervene in signal transduction of apoptotic path-
ways.11,12
Chaperonins are a subgroup of molecular chaperones
comprising high-molecular-weight oligomers that mediate
ATP-dependent folding of proteins that are resistant to
handling by simpler chaperones.13 On the basis of their
sequence homology, chaperonins are divided into two dis-
tinct subgroups: Group I chaperonins (bacterial GroEL/mi-
tochondrial Hsp60s) are found in prokaryotic cytosol and
endosymbiotic organelles such as mitochondria and chlo-
roplasts, and their function depends on cooperation with
speciﬁc cochaperonin molecules (bacterial GroES/mito-
chondrial Hsp10s). Group II chaperonins reside in archaeal
and eukaryotic cytosol and, although they are cochapero-
nin independent, are nevertheless assisted by other cofac-
tors, such as prefoldin.10,11 The mitochondrial Hsp60
chaperonin is one of the most important components of
the protein-folding system inside the mitochondrial ma-
trix. Hsp60 together with its cochaperonin Hsp10 produce
a large, efﬁcient protein-editing machinery that facilitates
proper folding and assembly of mitochondrial-imported
proteins and corrects misfolded polypeptides generated
under mitochondrial oxidative stress.14–16 Two mutations
in the HSPD1 gene encoding Hsp60 have recently been
found to underlie spastic paraplegia 13 (SPG13 [MIM
605280]), an autosomal-dominant spinal-cord neurode-
generative disorder of late onset, characterized by progres-
sive weakness and spasticity of the lower limbs.17,18
SPG13 is a member of the hereditary spastic paraplegia
group of disorders (SPGs). To date, 33 single-gene disorders
attributed to mutations in 15 identiﬁed genes have been
reported, affecting one in 10,000–100,000 persons.19,20
Traditionally, disorders within this group are classiﬁed ac-
cording to both the mode of inheritance and their clinical
features. They can be transmitted with autosomal-domi-
nant, autosomal-recessive, or X-linked inheritance. The
SPGs are classiﬁed as ‘‘pure’’ if leg spasticity is the sole clin-
ical manifestation or as ‘‘complicated’’ when accompanied
by additional or systemic manifestations, such as optic
neuropathy, retinopathy, extrapyramidal disturbances, de-
mentia, ataxia, mental retardation, and deafness.19 Defects
in intracellular trafﬁcking and transport in myelination
processes, as well as abnormalities of mitochondrial pro-
teins, have been implicated in the pathogenesis of SPGs.21
Mitochondria are essential organelles that house energy-
producing respiratory complexes and represent the major
site of cellular reactive-oxygen production. They carry
out crucial anabolic reactions and important key functions
during apoptotic processes. Pathogenic mutations in gene
products expressed in the mitochondria, whether encoded
by mitochondrial or nuclear genomic DNA, cause mito-
chondrial diseases.22 Given the importance of these organ-
elles for cellular physiology, it is not surprising that
mitochondrial dysfunction plays a fundamental role inneurodegenerative diseases including SPGs.23 To date,
three SPGs have been reported to be associated with muta-
tions in nuclear-encoded mitochondrial proteins, includ-
ing paraplegin, Hsp60 and the REEP1 protein (SPG7
[MIM 602783], SPG13 [MIM 605280], and SPG31 [MIM
610250], respectively). The ﬁnding that these genes are
widely expressed and their encoded proteins localize tomi-
tochondria underscores the importance of mitochondrial
function in neurodegenerative diseases.
In the current study, we describe an autosomal-recessive
lethal hypomyelinating leukodystrophy in a large inbred
Israeli Bedouin kindred. By using homozygosity mapping
and mutation analysis of selected candidate genes within
a linked genomic interval on 2q32.3-q33, we have identi-
ﬁed a homozygous missense mutation, D29G, in HSPD1,
encoding the mitochondrial Hsp60 chaperonin. The path-
ogenic effect of the D29G mutation was veriﬁed by an
E. coliHsp60-Hsp10/GroES-GroEL complementation assay.
The disorder, which we have termed MitCHAP-60 disease,
causes a ‘‘complicated’’ SPG, which is allelic to the pure au-
tosomal-dominant SPG13. This ﬁnding provides evidence
for the pivotal role of themitochondrial Hsp60 chaperonin
in the process of normal brainmyelination and in the path-
ogenesis of hypomyelinating neurodegenerative disease.
Subjects and Methods
Patients
A highly consanguineous Israeli Bedouin kindred residing in sev-
eral adjacent villages of the Galilee region of northern Israel was
clinically and genetically investigated. Ten patients suffering
from an autosomal-recessive fatal neurodegenerative disorder
and 37 of their close relatives were included in the study. The study
protocol was approved by the Institutional Ethics Review Com-
mittee and by the National Committee for Genetic Studies of
the Israeli Ministry of Health, and informed consent was obtained
from all participants or their legal guardians.
Clinical and Laboratory Evaluation
All affected individuals were clinically evaluated by pediatric neu-
rologists and clinical specialists in pediatric metabolic disease.
Clinical and biochemical details of deceased family members
were collected from patients’ medical charts. Biochemical evalua-
tion with standard laboratory techniques included the following
in all patients: measurement of plasma pH and concentration in
plasma of glucose, electrolytes, liver, and muscle enzymes, BUN,
creatinine, total carbon dioxide, lactate, pyruvate, aminoacids,
very-long-chain fatty acids (VLCFAs), and isotransferrin, as well
as urinary aminoacids, organic acids, and cerebro-spinal ﬂuid
(CSF) lactate, pyruvate, and alanine levels. Histologic and histo-
chemical analyses of muscle biopsy specimens from four patients
were performed by standard techniques. Spectrophotometric mea-
surements of respiratory-chain enzyme activities and citrate syn-
thase as well as Southern-blot analyses for detection of mitochon-
drial DNA depletion were carried out in muscle-biopsy specimens
as previously reported.24,25 Electrophysiological tests, including
nerve conduction, electromyography, brain-stem auditory evoked
potentials, and visual evoked potentials were performed in nine
patients.The American Journal of Human Genetics 83, 30–42, July 2008 31
Brain Imaging
Eight patients underwent brain MRI, with 1.5 T system (GE Signa
9.1) in four patients and 0.5 T system (GE Gyrex) in the other four.
All patients were evaluated by conventional T1-weighted and T2-
weighted images. Fluid-attenuation inversion recovery (FLAIR),
diffusion-weighted images (DWI), and single-voxel proton MR
spectroscopy (MRS) were obtained in four of eight patients. MRS
voxels were located in the frontal white matter (WM) and in the
thalamic gray matter. Peak areas of N-acetylaspartate (NAA), cho-
line (Cho), creatine/phosphocreatine (Cr), myoinositol (mI), and
lactate (Lac) were assessed and metabolite ratios of NAA/Cr,
Cho/Cr, and mI/Cr were calculated.
Homozygosity Mapping and Linkage Analysis
Genomic DNA of all participants was extracted from peripheral
lymphocytes by standard methods.26 A genome-wide scan was
performed with 378 ﬂuorescently labeled microsatellite marker
pairs (Version 10 Human Screening Set-ABI Dyes, Research Genet-
ics/Invitrogen). Microsatellite markers were ampliﬁed by multi-
plex polymerase chain reaction (PCR) with standard protocols.
Amplicons were resolved with an ABI 310 sequencer system
(Perkin Elmer) and analyzed with Genscan 3.1 and Genotyper
2.1 software (Applied Biosystems).
Single-nucleotide polymorphism (SNP) genotyping of 58,495
markers was performed on Affymetrix Human Mapping 50k Xba
240 arrays (Affymetrix) according to instructions provided by
the manufacturer. In brief, 250 ng of genomic DNA from each sub-
ject was processed and labeled with reagents and protocols sup-
plied by the manufacturer. After hybridization, the arrays were
scanned with the GeneChip scanner 3000 with GeneChip Operat-
ing Software (GTYPE) version 1.4. Array CEL ﬁles were processed
with Gene-Chip DNA Analysis Software version 4.0. Raw data of
SNP genotyping results were sorted on Microsoft Ofﬁce Excel
sheets, and regions of homozygosity were detected and analyzed
by visual inspection.
Linkage to the GJA12 locus on 1q41-q42, veriﬁcation of linkage
to the locus on chromosome 2q32.3-q33.1, haplotype analysis,
and ﬁne mapping were performed by genotyping of additional
microsatellite markers derived from Marshﬁeld maps (Mammal-
ian Genotyping Service database of the Marshﬁeld clinic) in all
affected individuals included in the study and in their close
relatives.
Two-point LOD-score calculations for markers D2S2387,
D2S311, D2S2327, D2S316, D2S374, and D2S115 on 2q32.3-
q33.1 were performed with the SUPERLINK program.27 We as-
sumed an autosomal-recessive mode of inheritance with pene-
trance of 0.99, a disease mutant gene frequency of 0.01 and a
uniform distribution of allele frequencies.
Sequencing of Candidate Genes
Exploration of the entire coding sequence and intron-exon
boundaries of four candidate genes (MARS2 encoding the mito-
chondrial methionine-tRNA synthetase 2, COQ10B encoding
coenzyme Q10 homolog B, HSPD1 encoding the mitochondrial
chaperonin Hsp60, and HSPE1 encoding the mitochondrial chap-
eronin Hsp10 [GenBank accession number NC_000002.10]) and
of the intergenic region between HSPD1 and HSPE1 was initially
performed in one affected child (patient VIII-6 in the pedigree,
shown in Figure 1). Intronic primer pairs were designed with
the Gene Runner program version 3.05 (Hastings Software), based
upon DNA sequences obtained from UCSC Genome Browser.32 The American Journal of Human Genetics 83, 30–42, July 2008Primer sequences and annealing temperatures used in PCRs for
HSPD1 are shown in Table 1. Those used for MARS2, COQ10B,
HSPE1, and the intergenic region between HSPD1 and HSPE1
are available on request. Amplicons were directly sequenced
with the BigDye terminator sequencing system (Perkin Elmer
Applied Biosystems) on an ABI PRISM 3100 sequencer (Perkin
Elmer). Sequence variations were conﬁrmed by bidirectional
sequencing.
Mutation Detection by Mismatch Primer
Restriction Assay
A mismatch restriction-fragment-length polymorphism (RFLP)
assay was constructed and utilized for mutation detection in in-
vestigated family members and in healthy controls. Because
the g.1512A/G (D29G) mutation in exon 2 of HSPD1 could
not be identiﬁed by any known restriction enzyme, we
designed a 30-bp-long mismatching forward primer and a match-
ing reverse primer to amplify a 124-bp-long fragment encompass-
ing the mutation (see Table 1 for RFLP primer sequences). Table 1
shows the RFLP primer sequences, with the two consecutive mis-
matching C nucleotides in the forward primer located 9 and 10 bp
50 to g.1512A highlighted in bold. Amplicons containing both the
mismatching forward primer and the g.1512A/G mutation in-
troduced a BslI (New-England Biolabs) restriction site, which di-
gested the 124 bp product into 94 bp and 30 bp fragments. Frag-
ments were separated by electrophoresis on 5% MetaPhor
Agarose gel.
Multiple Protein Alignment
Analysis of conservation of the D29 residue in Hsp60 was per-
formed by multiple sequence alignment of ten Hsp60 homolog
proteins from various species with the ClustalW software with
a Java viewer. Species-speciﬁc Hsp60 homolog sequences were
derived from the MitoRes database.
E. coli Complementation Assay
The GroEL-GroES group I bacterial chaperonin complex is the
E. coli homolog of mitochondrial Hsp60-Hsp10 and is essential
for bacterial survival under all conditions tested.28 It was previ-
ously shown that expression of the human Hsp60-Hsp10 genes
can complement deleted GroEL-GroES in E. coli strains and effec-
tively support bacterial growth at moderate temperatures.29,30
On the basis of these ﬁndings, we performed an E. coli comple-
mentation assay, essentially as previously described,17,30 to exper-
imentally determine the ability of the D29G-Hsp60 variant to sup-
port E. coli survival. In brief, we used a GroEL-GroES deletion allele
marked with both a Chloramphenicol-resistance (CamR) cassette
in the operon and a Tetracycline-resistance (TetR) cassette nearby
on the chromosome to replace the wild-type (WT) GroEL-GroES
operon in our test strains by T4gt7 phage-mediated transduc-
tion.30 Besides the WT GroEL-GroES operon on the chromosome,
the test strains also carry plasmid pOFX (Kanamycin resistant
[KanR], isopropyl-b-D-fthiogalactopyranoside [IPTG]-inducible ex-
pression) containing either the WT human Hsp60-Hsp10 set of
genes or the Hsp60(D29G)-Hsp10(WT) variant. Fresh transduc-
tants were ﬁrst selected for TetR by incubation on LB-agar plates
containing 12.5 mg/ml of tetracycline and 500 mM IPTG at 30C
for 48 hr. These were then tested for CamR, indicating that the de-
letion allele had replaced the WT GroEL-GroES operon on the
chromosome. Because the cotransduction frequency between
the two resistance markers was normal (90%), and so that the
Figure 1. Pedigree of the Analyzed Subjects
The inheritance of the disease is compatible with an autosomal-recessive trait. Roman capitals indicate generations. Arabic numerals
indicate serial numbers of study participants. Blackened symbols indicate affected individuals. Diagonal lines across symbols indicate
deceased individuals. Asterisks indicate affected individuals who underwent DNA analysis.risk of accumulating nonspeciﬁc suppressors was minimized, in
subsequent experiments GroEL-GroES-deleted transductants
were directly selected for CamR at 30C in the presence of 500
mM IPTG for 48 hr. Single colonies from independent transduc-
tions (12 expressing the D29G mutant and 12 expressing WT
Hsp60) were resuspended in 10 mM MgSO4, diluted serially 20-
fold, and spotted on LB-agar plates containing varying amounts
of IPTG inducer and 12.5 mg/ml of chloramphenicol; this was fol-
lowed by incubation at 30C, 37C, and 38.5C for various times.
Measurement of Hsp60 Levels
To verify equivalent levels of Hsp60 expression by E. coli contain-
ing the various plasmid constructs, we performedmeasurement of
WT and D29G mutant Hsp60 protein levels by western blotting
and quantitative immunoassay. All analyses were performed on
seven independent GroEL-GroES-positive cultures (GroESL-plus)
and seven independent GroEL-GroES-deleted cultures (GroESL-
minus). Each group of seven cultures was transformed with either
WT or D29G-Hsp60 mutant plasmid. Western blotting was per-
formed by standard procedures,15 and quantitative immunoassay
of Hsp60 was performed at room temperature with xMAP technol-
ogy as previously described.31
Results
Clinical and Laboratory Evaluation
Over the past decade, 23 children of the family investigated
in the current study have been diagnosed as suffering from
an autosomal-recessive fatal neurodegenerative disorder of
early onset, associated with hypomyelinating leukodystro-phy (see pedigree in Figure 1). The clinical features of ten af-
fected individuals are presented in Table 2. Early clinical
manifestations in all patients included hypotonia, nystag-
mus, and psychomotor developmental delay, followed by
appearance of prominent spasticity, developmental arrest,
and regression. Head circumference, which was normal at
birth, showeddecreased growth rate. Seizureswere reported
in six patients. Feeding problems commonly led to malnu-
trition and growth failure. Death usually occurred within
the ﬁrst two decades of life from aspiration pneumonia or
sudden death of unknown cause. One of the most extreme
presentationswas hydrops fetalis in one patient, who even-
tually died at the age of 2 years. Patients with the more
severe course died before the age of 2 years, with some of
themnever gaining social eye contact or anyother develop-
mental milestone. These severely affected patients suffered
from recurrent episodes of shallow breathing and apneic
spells during acute febrile illnesses and died during such ep-
isodes. In patients who survived beyond the age of 2 years,
the motor disability, which mainly included progressive
limb spasticity and contractures, seemed to be more prom-
inent than the psychointellectual impairment. Patients
with greater longevity (at present, the oldest surviving pa-
tient is age 14 years of age) sometimes showed improve-
ment of nystagmus, but all suffered from strabismus and
lack of normal head control, in addition to choreoatetotic
movements in some. A wide range of intrafamilial and in-
terfamilial phenotypic heterogeneity at the level of psycho-
motor impairment and in the rate of neurologic andThe American Journal of Human Genetics 83, 30–42, July 2008 33
Table 1. Primer Sequences and Annealing Temperatures for HSPD1 Sequence Analysis
Primer Sequence (50/30)
PCR Product
Size (bp)
Annealing
Temp (C)Exon Forward Reverse
2 GCTCAGCATCTCACGTTG ATCCACCTTGAGCTGTAAG 537 53
3 TGAGACTTTGAAGTAGTTGC ACCTACCCACCATACAGC 535 51
4 TTGACATAGAAGCCATGAG ACCTTTGACAATGGCTAAG 533 51
5 TCAATTTGGAAGTTACTAGG GGTAGAGTATGAAACAGCC 488 54
6 GCTGTTTCATACTCTACCC CAGCTACTTGGGAGACTG 388 55
7 ATTAGTTGGTGTCATCCTC ATCAAATGTGGAGGTACAC 456 53
8 CCAGATTACTTAGGGAGTCC AGTCAGTAAGCTCATTCTTAGG 391 57
9 GGAAATGCAGTGAAAGAG GTTAATTCCTCAAGTATTCG 537 50
10 TAGTGGAGACAGGGCTTCAC TGTGATGCATGTTTAGCTCTG 540 57
11 ATTTCCCTACATCAATATCC CATGAGAATTGTTGATGGG 418 54
12 GGTCTTGAACTCCTAACCTC GTTATTGGTGAGGAACACTGC 378 61
Exon 2, mismatch RFLP CTCCTCATCTCACTCGGGCTCCTGCCAAAG GGTACCTTTGGCCCCATTGTAACGG 124 64developmental deterioration was evident among affected
individuals carrying the same HSPD1mutation.
Routine and extensive metabolic laboratory investiga-
tion including blood glucose, electrolytes, liver andmuscle
enzymes, kidney-function tests, pH, bicarbonate, VLCFA,
isotransferrin, serum, urinary amino acids, plasma, and
CSF lactate, pyruvate, and alanine did not reveal any spe-
ciﬁc biochemical marker associated with the investigated
disorder. However, in ﬁve of eight studied patients in
whom we conducted urinary organic amino acid measure-
ments, we found intermittently markedly increased uri-
nary secretion of ethylmalonic (25–169 mmol/mol creati-
nine; normal % 12) and to a lesser extent methylsuccinic
acids. The highest level of urinary ethylmalonic acid was
found in the patient who presented with hydrops fetalis.
In three of ﬁve of these patients, we also found elevated
levels of C4 acylcarnitine.
The plasma lactate level, which is considered as a basic
screening marker for mitochondrial respiratory-chain de-
fects, was found to be normal, except for mild elevation,
i.e., 2.6–4.2 mmol/l, documented in four patients during
acute encephalopathic exacerbations (normal level % 2).
Of note, CSF lactate pyruvate and alanine levels were nor-
mal in all six patients in whom this was measured, even
during episodes of acute deterioration.
In all four muscle biopsies performed, no evidence of mi-
tochondrial function impairment, such as ragged-red ﬁbers
or cytochrome c oxidase (COX)-deﬁcient ﬁbers, was found.
However, in one patient examined, we found ultrastruc-
tural changes in the muscle as manifested by morphologi-
cally giant mitochondria with abnormal cristae (results not
shown). Only in the most severely affected patient with
hydrops fetalis did we observe mildly reduced activity of
COX (40% of control level).
No major abnormalities were found in nerve conduc-
tion and electromyography studies. Brain-stem auditory-
evoked-potential studies showed increased latency of
wave I and absence or small size of later components, de-
noting brain-stem abnormalities. Visual evoked potentials
were abnormal with slowing latency and aberrant wave
shape in two of three studied patients.34 The American Journal of Human Genetics 83, 30–42, July 2008MRI/MRS
Because all parents declined autopsy of their deceased
children, no brain specimens were available for histopath-
ologic analysis. MRI enables noninvasive visualization of
abnormal myelination and was therefore used as a diag-
nostic tool for anatomic evaluation of the investigated
neurodegenerative brain disorder. In all patients examined,
the youngest of whom was a 5-month-old infant, all cere-
bral and cerebellar white-matter structures as well as the
corticospinal tracts were of high signal intensity on
Table 2. Clinical Characteristics of Ten MitCHAP-60 Patients
Characteristic
Number of
Patients
Affected individuals included in the study 10
Age at onset of symptoms between birth to 3 months 10/10
Deceased <2 years of age 3/10
Deceased between 5 and 12 years of age 2/10
Alive at present (11 months to 14 years of age) 5/10
No head control 10/10
Head titubation 10/10
Truncal hypotonia 10/10
Spastic paraplegia, increased tendon reflexes/
positive Babinski sign
10/10
Strabismus 10/10
Nystagmus 9/10
Psychomotor retardation 10/10
Severe 8/10
Some social interaction and few words 2/10
Rate of disease progression/deterioration
Rapid (died prior to 2 years of age) 3/10
Slow 7/10
Seizures 6/10
Exacerbation during febrile episodes 10/10
Episodes of abnormal breathing/apneic spells (more
often in patients deceased prior to 2 years of age)
6/10
MRI showing hypomyelinating leukodystrophy 8/8
BERA results compatible with abnormal brain-stem
function
9/9
Elevated urinary ethylmalonic acid levels 5/8
Elevated plasma lactate during acute illness with
normal CSF lactate
4/10
6/6
Muscle biopsy
Electron microscopy—abnormal 1/4
Cytochrome c oxidase activity—mildly reduced 1/4
T2-weighted images (Figures2A–2C). Therewasnoevidence
of normal myelination, regardless of the age of the patient.
All patients exhibited a thin corpus callosum and showed
various degrees of ventricular enlargement. Enlargement
of sulci and subarachnoid spaces, mainly in the frontal
and parietal areas, were observed in six of eight patients.
The degree of widening of cerebral sulci was in concordance
with the severity of the clinical symptoms. The brain stem
was thin in all patients (Figure 2A). In ﬁve of eight patients,
the cerebellum and vermis were smaller than normal for
age. DWI disclosed high signal intensity along the cortico-
spinal tractswithdecreased values onapparentdiffusion co-
efﬁcient (ADC) maps, indicating restricted diffusion. One
patienthad twoMRI studies, theﬁrst at theageof10months
and the second at 2.5 years of age. In the latter study, the
cisternamagna and cerebellar and vermian sulci were wider
in size as compared to those of the earlier study, suggesting
progressive cerebellar atrophy. The cerebral hemispheres
did not exhibit signiﬁcant changes in size or intensity, and
the cerebral subarachnoid spaces maintained their original
size.OnMRS studies performedon the frontal whitematter,
increased mI/Cr ratios and normal Cho/Cr ratios were
found in all patients. The NAA/Cr ratio was normal or
slightly reduced. Abnormal accumulation of lactate was de-
tected in only two patients with neonatal disease presenta-
tion. MRS detected slightly reduced NAA/Cr ratio in the
thalamus (gray matter) (Figure 2E).
HSPD1 Mapping on 2q32.3-q33.1
Genotyping of polymorphic DNA markers ﬂanking GJA12
on 1q41-q42 failed to reveal linkage with the disease phe-
notype, thus ruling out a connexin 47 defect as the cause
for the investigated disorder in this kindred. A microsatel-
lite-based genome-wide scan with the 378 Research Genet-
ics/Invitrogen marker set performed in six affected chil-
Figure 2. MRI/MRS Brain Imaging
(A–C) Axial T2WI in a 17-month-old patient showing
high intensity of the white matter consistent with the
complete absence of myelin.
(D) Sagital T1WI of a 16-month-old patient demon-
strating a small brain stem and atrophy of the cere-
bellum and vermis.
(E) Proton MR spectroscopy MRS (TE ¼ 35) of a 16-
month-old patient disclosing a reduced NAA/Cr ratio
and increased mI/Cr ratio in the white matter, a nor-
mal Cho/Creatine ratio consistent with hypomyelina-
tion rather than with myelin destruction, and peaks
for lactate and lipids, consistent with defective oxi-
dative phosphorylation.
dren (subjects VIII-3, VIII-6, VIII-11, VIII-12,
VIII-15, and VIII-20 in the pedigree, shown
in Figure 1) failed to reveal linkage to a speciﬁc
chromosomal locus. Accordingly, we turned
to a 50,000-SNP-marker-microarray genome-
wide scan, which was performed in three
affected children (subjects VIII-3, VIII-6, and VIII-13).
The call rate was > 97%, and visual inspection of SNP ge-
notypes revealed a 4.58 Mb long continuous segment of
shared homozygosity among all three patients, spanning
103 consecutive SNPs between markers rs1478129 and
rs1379020 (at physical positions 194,382,571 and
198,963,363, respectively), on chromosome 2q32.3-
q33.1. In two of the three analyzed patients (VIII-3 and
VIII-13), the shared regions of homozygosity were con-
tained within very large stretches of homozygosity of
14.1 Mb and 47.7 Mb, respectively. We also found ﬁve
additional signiﬁcantly smaller regions of shared homozy-
gosity on chromosomes 1, 2, 4, 17, and 20, ranging in
length between 1.0–1.5 Mb. However, because none of
these were contained within larger stretches of individual
homozygosity, we ﬁrst analyzed the region of suggestive
linkage on 2q32.3-q33.1. This region includes the microsa-
tellite marker D2S117 (at physical position 195,327,044),
contained in the Research Genetics/Invitrogen marker
set. Genotyping of D2S117 failed to show linkage to the
disease, thus narrowing down the linked interval to
a 3.6-Mb-long segment within 2q32.3-q33.1. Linkage to
the locus on 2q32.3-q33.1 was conﬁrmed by genotyping
of six additional microsatellite markers contained within
the homozygous interval in ten affected children and their
close relatives (Figure 3). The maximum two-point LOD
score was 6.4 for marker D2S374 at a recombination frac-
tion (q) ¼ 0.00 (Table 3). All affected individuals share
a common homozygous haplotype between markers
D2S117 and D2S1384, supporting a common ancestral
origin for the linked locus on 2q32.3-q33.1.
Mutation Analysis
Of the 23 genes contained within the linked region (NCBI
Map Viewer, build 36.2), 18 are of known function and ﬁveThe American Journal of Human Genetics 83, 30–42, July 2008 35
Figure 3. Haplotype Analysis
Confirmation of linkage was performed by genotyping of eight polymorphic microsatellite markers within the SNP-based candidate region
on 2q32.3-q33.1 in ten affected children and their close relatives. Blackened symbols and diagonal lines across symbols indicate affected
and deceased individuals, respectively. Numbers below symbols correspond to the position of individuals within the pedigree (see Figure 1
for details). Hyphens indicate nongenotyped markers. The shared disease-associated haplotype is shown in boxes.are predicted protein coding genes of unknown role. Of the
18 known genes, eight were ruled out as disease-associated
candidates on the basis of their known function or tissue
expression (data derived from Online Mendelian Inheri-
tance in Man [OMIM] and GeneCards databases). Of the
ten remaining candidates, we ﬁrst chose to sequence four
genes implicated in normal mitochondrial function, on
the basis of increasing evidence suggesting the potential
role of mitochondrial dysfunction in the pathogenesis of
neurodegenerative disorders.32–35
Sequencing was initially performed on genomic DNA de-
rived from patient VIII-6. Sequence analysis of all coding
exons and intron-exon boundaries of MARS2 COQ10B
andHSPE1 revealed no sequence variations. Sequence anal-
ysis of HSPD1 encoding Hsp60 revealed two sequence vari-
ations: (1) a homozygous missense mutation g.1512A/G
in exon 2 at position 86 of the cDNA sequence, causing
an aspartic acid/glycine exchange at amino acid 29 of
the Hsp60 protein sequence (D29G) (Figure 4A) and (2) a
known homozygous synonymous SNP g.2981A/G
(rs8539, according to NCBI dbSNP database) in exon 3 at
position 273 of the cDNA sequence, encoding a lysine resi-
due at position 91 of the Hsp60 protein sequence and
resulting in no amino acid change. Sequencing of the
HSPD1-HSPE1 intergenic region containing the bidirec-
tional promoter region for these two mitochondrial
chaperonins revealed a previously described homozygous
sequence variation g.3175G/C36 (rs1116734 according
to NCBI dbSNP database).
Of the three identiﬁed sequence variations, only the
D29G mutation in HSPD1 segregated completely with the
disease; all ten affected children were homozygous for
the mutation and all parents were heterozygous, whereas
healthy siblings were either heterozygous or wild-type in
a manner consistent with haplotype analysis. Most unaf-
fected individuals were homozygous for both of the known
SNPs, g.2981A/G in exon 3 ofHSPD1 and g.3175G/C in36 The American Journal of Human Genetics 83, 30–42, July 2008the HSPD1-HSPE1 intergenic region, thus ruling out segre-
gation of these sequence variations with the disease.
The D29G variant of HSPD1 was veriﬁed by the mis-
match restriction assay (Figure 4B), and the RFLP pattern
was compatible with exon 2 sequencing results in all inves-
tigated family members. The D29Gmutation was not pres-
ent in 678 chromosomes of healthy ethnically matched
control samples.
The D29 residue was found to be highly conserved across
Hsp60 homologs from nine different nonhuman species
(Figure 4C) and is containedwithin a conserved domain ad-
jacent to the ﬁrst 26N-terminal residues composing themi-
tochondrialmatrix targeting sequence (according toHsp60
predicted domains derived from Swiss-Prot database, acces-
sion number P10809). In an alignment of human Hsp60
with the E. coliHsp60 homolog GroEL, the humanD29 res-
idue corresponds to D5 in E. coli GroEL. Inspection of the
crystal structure of E. coli GroEL37 shows that D5 is located
within the ﬁrst b strand of the GroEL equatorial domain,
facing the interior of the chaperonin central cavity.
E. coli Complementation Assay and Measurement
of Hsp60 Levels
E. coliB178 carrying aplasmidwith eitherWTHsp60-Hsp10
or Hsp60(D29G)-Hsp10(WT) was the recipient in transduc-
tion experiments replacing theWTGroEL-GroESoperonon
Table 3. Two-Point LOD Scores for Markers on 2q32.3-q33.1
Locus LOD at q ¼ 0.00
D2S117 3.9516
D2S2387 4.4752
D2S311 3.23.4
D2S2327 3.5143
D2S316 3.5791
D2S374 6.3972
D2S115 4.0681
Figure 4. HSPD1 Mutation Analysis
(A) Genomic DNA sequence analysis of
HSPD1 reveals a homozygous A/G transi-
tion at position g.1512 (indicated by an
arrow) in exon 2, resulting in an aspartic-
acid-to-glycine substitution at position
29 of the Hsp60 protein (D29G). The muta-
tion is carried in a homozygous state by an
affected child (left panel) and in a hetero-
zygous state by his mother (middle panel).
A healthy control shows the wild-type (WT)
sequence (right panel).
(B) Confirmation of the D29G mutation in
an affected individual and his close rela-
tives by mismatch PCR-RFLP. Numbers ad-
jacent to symbols correspond to the posi-
tion of individuals within the pedigree
(see Figure 1 for details). PCR amplification
was performed as described in the text. Amplicons containing both the mismatching forward primer and the D29G mutation in exon 2 of
HSPD1 introduce a recognition site for BslI, which digests the 124 bp PCR product into 94 bp and 30 bp fragments. Homozygous carriers of
the mutation display a 94 bp fragment (the additional 30 bp fragment is not shown), healthy individuals carrying the wild-type sequence
show a 124-bp fragment, and heterozygous carriers of the mutation display two fragments of 124 bp and 94 bp.
(C) ClustalW analysis of the Hsp60 N-terminal region encompassing the mutation site demonstrates that the D29 residue (highlighted in
red) is highly conserved across Hsp60 homologs from various species. The D29 residue in human Hsp60 corresponds to D5 in the E. coli
homolog protein because of the lack of a mitochondrial-targeting sequence in bacteria.the chromosome with a deleted version marked with a
CamR gene. The cotransduction frequency with a nearby
TetR marker was 90% for both WT (90/100) and D29G-
Hsp60-expressing cells (88/100). This indicates that the
plasmid-encodedWTHsp60andHsp60(D29G)mutantpro-
teins both support E. coli survival under these conditions.
More extensive complementation assays showed that
all E. coli transductants that lost the GroEL-GroES locus
and were kept alive with the pOFX mutant Hsp60(D29G)-
Hsp10(WT) plasmid grew signiﬁcantly more slowly and
were more temperature sensitive than the corresponding
Hsp60(WT)-Hsp10(WT) cells under all conditions tested,
except at 30C on 500 mM IPTG plates, in which growth
was similar. At lower IPTG concentrations, however, the
D29G mutants grew much more slowly than the wild-
type, even at 30C (Figure 5).
Measurements of intracellular Hsp60 levels by quantita-
tive immunoassay (Figure 5) and by western-blot analysis
(data not shown) revealed comparable levels of WT and
D29G-Hsp60 mutant protein expression, thus ruling out
thepossibilityof increased temperature sensitivityofmutant
E. coli transductantsdue to reducedD29G-Hsp60expression.
All these experiments taken together clearly show that
bacteria expressing the D29G variant grow considerably
more slowly than WT cells under most conditions tested,
and especially at elevated temperatures (37C and
38.5C), indicating that the D29G variant is signiﬁcantly
compromised in its chaperone function.
Discussion
In the current study, we describe an autosomal-recessive
hypomyelinating leukodystrophy caused by a missensemutation in the mitochondrial Hsp60 chaperonin, which
we have accordingly termed MitCHAP-60 disease. The
ten patients studied exhibited the following shared cardi-
nal features: (1) rotatory nystagmus, which was the pre-
senting symptom in most patients; (2) progressive spastic
paraplegia within the ﬁrstmonths of life, followed by a var-
iable rate of neurological deterioration and regression; (3)
severe motor impairment, with none of the affected chil-
dren ever gaining normal head control; (4) profound men-
tal retardation; and (5) hypomyelinating leukodystrophy
as evidenced by brain MRI.
The use of homozygosity mapping and then mutation
analysis of candidate genes within the linked locus on
2q32.3-q33.1 enabled us to pinpoint a homozygous mis-
sensemutation (D29G) inHSPD1, encoding themitochon-
drial Hsp60, as responsible for MitCHAP-60 disease. The
ﬁnding of the D29G missense mutation was surprising,
given the fact that disease-causing mutations in human
Hsp60 have so far been exclusively identiﬁed in individ-
uals suffering from SPG13, a relatively mild and late-onset
form of hereditary SPG transmitted in an autosomal-dom-
inant pattern.17,18 SPG13 represents an uncomplicated
form of hereditary SPG. To date, two pathogenic heterozy-
gous missense mutations in HSPD1 have been identiﬁed in
families with SPG13: V98I in seven affected adults from
a French family and Q461E in a 58-year-old woman from
a Danish family. In both families, the disease was transmit-
ted as a late-onset autosomal-dominant trait, with variable
penetrance. Whereas the V98I-Hsp60mutation was associ-
ated with an age-dependent, highly penetrant disorder, the
Q461E mutant exhibited much lower penetrance, as sug-
gested by the ﬁnding of asymptomatic heterozygous car-
riers in their sixth or seventh decade.17,18 These differencesThe American Journal of Human Genetics 83, 30–42, July 2008 37
in penetrance correlated with the results of E. coli comple-
mentation assays with the two identiﬁed HSPD1 muta-
tions; these results showed that the V98I variant was com-
pletely unable to support the survival of GroEL-GroES
deleted bacteria, whereas the Q461E variant only mildly
compromised bacterial growth. The results of these func-
tional tests suggest the existence of a genotype-phenotype
correlation between the functional pathogenicity of
HSPD1mutations in the complementation assay and clin-
ical disease severity or penetrance.
The current HSPD1 missense mutation identiﬁed in
MitCHAP-60 results in a substitution of aspartic acid for
glycine at amino acid 29 of the Hsp60 protein. Several ﬁnd-
ings support the causative role of the D29G mutation in
the pathogenesis of MitCHAP-60 disease. These include
(1) complete segregation of the mutation with the dis-
ease-associated phenotype in all investigated family mem-
bers; (2) the absence of the mutation in a large number of
Figure 5. E. coli Complementation Assay
(A) Impaired growth of GroEL-GroES-deleted E. coli cells comple-
mented with the D29G-Hsp60 variant under various conditions. Sin-
gle, fresh transductant colonies (12 expressing the wild-type Hsp60
and 12 expressing the mutant D29G-Hsp60) were resuspended in 10
mM MgSO4; 20-fold serial dilutions were made, alternately spotted
on LB agar plates containing varying amounts of IPTG inducer and
12.5 mg/ml of chloramphenicol, and incubated at various tempera-
tures. Growth impairment of serial dilutions of mutant as compared
to wild-type transductans alternating from left to right at 30C in
25 mM IPTG (left panel), at 37C in 25 mM IPTG (middle panel)
and at 38.5C in 500 mM IPTG (right panel) is shown.
(B) Measurement of Hsp60 expression in GroEL-GroES-deleted
E. coli transductants by immunoassay. The mean expression levels
of Hsp60 in eight individual bacterial transductants, four express-
ing the wild-type Hsp60 (WT) and four expressing the mutant
D29G-Hsp60 (mutant), were found to be comparable (p value for
two-sample Student’s t test ¼ 0.47). Error bars indicate the stan-
dard error of the mean.38 The American Journal of Human Genetics 83, 30–42, July 2008ethnically matched controls; (3) the high degree of conser-
vation of the D29 residue across Hsp60 homologs of vari-
ous nonhuman species, from vertebrates to bacteria, sug-
gesting its functional importance; and (4) the E. coli
complementation-assay results, which clearly demonstrate
the markedly reduced ability of the D29G-Hsp60 mutant
protein to support E. coli survival at all temperatures, but
especially at the higher ones. Taken together, all these ﬁnd-
ings strongly suggest that the homozygous state of the
g.1512A/G mutation of HSPD1 resulting in the D29G
mutation compromises Hsp60 protein function and is re-
sponsible for the severe phenotype of MitCHAP-60 disease.
The fact that E. coli survival was not completely abol-
ished by the D29G-Hsp60 variant suggests that the D29G
substitution may exert a less severe effect on Hsp60 func-
tion, as compared to the previously described Hsp60-
V98I variant causing SPG13. This result is not surprising,
given the fact that all heterozygous carriers of the D29G
mutation in our study are completely asymptomatic,
with some of the carriers reaching their ninth decade of
life, suggesting that a single D29G mutant allele does not
signiﬁcantly impair overall mitochondrial Hsp60 activity.
The mechanisms by which HSPD1 mutations in general
and the D29G-Hsp60 variant in particular may compro-
mise normal Hsp60-chaperonin function is not well un-
derstood. According to the inferred structures of GroEL,
the E. coli homolog of Hsp60, all bacterial equivalents of
the disease causing Hsp60 substituted residues that have
been identiﬁed so far (i.e., V98, Q461, and D29) are located
within the equatorial domain of the chaperonin mole-
cule.37,17,18 In vitro studies have shown that the V98I var-
iant Hsp60 protein forms heptameric chaperonin com-
plexes but displays strongly reduced chaperone activity
withmalate dehydrogenase as a substrate.31 The speciﬁc ef-
fect of the D29Gmutation onHsp60 conformational struc-
ture and chaperonin activity remains to be delineated.
Moreover, it is unclear whether the two additional and
apparently nonpathogenic SNPs identiﬁed in HSPD1 of
MitCHAP-60 patients (i.e., g.2981A/G in exon 3 and
g.3175G/C in the HSPD1-HSPE1 intergenic region) also
exert a modiﬁer effect on Hsp60 conformation and func-
tion, especially in combination with the D29G mutation.
Of special interest are the potential mechanisms by
which different mutations in HSPD1may lead to such dra-
matic differences in both the pattern of inheritance and
the disease phenotype between SPG13 and MitCHAP-60.
It has been previously postulated that the autosomal-dom-
inant inheritance of SPG13 results from a dominant-nega-
tive effect exerted by defective Hsp60monomers on proper
assembly of the whole oligomeric chaperonin molecule.17
However, recent in vivo experiments in a bacterial model
system indicate that heterologous complexes consisting
of both wild-type and V98I mutant Hsp60 subunits are
formed and that incorporation of mutant subunits does
not result in a strong dominant-negative effect.31 One
would also not expect the D29G subunits to exert any sig-
niﬁcant dominant-negative effect in mixed oligomers with
the Hsp60WT because there is no observable phenotype in
the heterozygous state. Consistent with our functional
analyses, different patterns of inheritance of MitCHAP-60
and SPG13 may thus be explained in the following way:
The D29Gmutation, which exerts a relatively milder effect
on Hsp60 function, only manifests in the homozygous
state, whereas the V98I mutation, having a more severe
effect on Hsp60 activity, produces a phenotype in the het-
erozygous state. Nevertheless, homozygosity for the mild
mutation causes a more severe phenotype than heterozy-
gosity for the severe one.
The link betweenmitochondrial derangements and neu-
rodegenerative diseases is well known32–35 and served as
the initial impetus to consider the HSPD1 gene as a candi-
date for MitCHAP-60. Because Hsp60 is a mitochondrial
chaperonin, it is reasonable to assume that neuronal dam-
age is initiated by some form of mitochondrial dysfunc-
tion. Experiments in yeast have shown that null mutations
of Hsp60 render the cells nonviable, secondary to severe
mitochondrial-protein-folding defects, whereas those
with conditionalmutations accumulatemisfolded proteins
that are incapable of forming active oxidative-phosphory-
lation enzyme complexes.38 In another recent in vitro
experiment using neuronal cells, Hsp60 was shown to
exert a protective effect on vital mitochondrial respira-
tory-chain enzymes against poisoning by b-amyloid, indi-
cating the preventive effect of Hsp60 against mitochon-
drial damage.39 Of interest is the ﬁnding that defects in
paraplegin, another nuclear-encoded mitochondrial pro-
tein with chaperone-like function, are the cause of SPG7,
a complicated form of autosomal-recessive SPG.40 Taken
together, all these ﬁndings suggest that mitochondrial
chaperonin defects exert a profound impact on overall mi-
tochondrial biogenesis, integrity, and function. The ab-
sence of some of the classical clinical and laboratory man-
ifestations of impaired electron-transport-chain activity in
MitCHAP-60 disease, such as evidence of elevated lactic-
acid production or reduced activity of respiratory-chain
complexes, is suggestive of diverse cellular effects of mito-
chondrial dysfunction besides impaired oxidative phos-
phorylation for production of ATP. Among others, these
include exaggerated production of reactive-oxygen species
or apoptosis, which may underlie the neuronal-disease
phenotype exhibited by the MitCHAP-60 patients and is
reminiscent of the pathogenesis of Leber’s hereditary optic
atrophy.35
It is possible that one of the most important means of
understanding the precise mechanisms leading to neuro-
degeneration secondary to Hsp60 defects depends on iden-
tifying the biochemical interactions of the Hsp60-Hsp10
mitochondrial machinery with its various protein sub-
strates, both under physiologic conditions as well as dur-
ing biophysical stress or toxic cellular-protein overload.
Unfortunately, the full range of Hsp60 substrates has not
yet been delineated in human mitochondria. It is reason-
able to assume that various Hsp60 disease-causing muta-
tions differ in the type and extent of substrate-processingdefects they exert. Identifying those substrates that are crit-
ically dependent on Hsp60 functionmay shed light on dis-
ease mechanisms related to their native biological func-
tion. In this regard, it is interesting that our MitCHAP-60
patients were found to have intermittently increased ex-
cretion of ethylmalonic acid (EMA), mainly during acute
febrile episodes. EMA is considered a biochemical marker
for short-chain acyl-CoA dehydrogenase deﬁciency
(SCAD deﬁciency [MIM 201470]). In vitro studies have
shown that interaction of Hsp60 with SCAD is crucial for
correct folding of the latter.41,42 Thus, the increased uri-
nary EMA in MitCHAP-60 patients may indicate either
a causative or sentinel role of abnormal biogenesis of
SCAD proteins associated with the Hsp60 function defect.
Although most cellular Hsp60 is localized to the mito-
chondria, ~15%–20% of the protein is located at extrami-
tochondrial sites.43 Growing evidence connects cytosolic
accumulation of Hsp60 with apoptosis under both physio-
logic and disease states.44–46 The rostral ventrolateral me-
dulla (RVLM) of the brain stem governs central cardiovas-
cular regulatory integrity, and its disruption leads to
brain-stem death. With an experimental model of endo-
toxemia, it has been shown that redistribution of Hsp60
from the mitochondria to the cytosol in the RVLM exerts
a neuroprotective effect against fatal cardiovascular depres-
sion by inhibiting apoptosis.44,45 During acute febrile ill-
nesses, several MitCHAP-60 patients suffered from epi-
sodes ranging from disordered breathing with apneic
spells to cardiac dysrrhythmias with unexplained sudden
death. These phenotypic features combined with brain
stem and medullary atrophy depicted in brain MRI images
could reﬂect in vivo abnormal regulation of RVLM caused
by compromised cytosolic Hsp60 function.
Hypomyelination has been reported in association with
several established disorders, including the prototype
PMD, PMLD, Cockayne syndrome type B (CSB [MIM
133540]), hypomyelination, atrophy of the basal ganglia
and cerebellum, and hypomyelination and congenital cat-
aract syndrome (HCC [MIM 610532]), among others.47
Analysis of mutations in PLP1 encoding the major protein
of CNS myelin has revealed the previously unappreciated
role of glial myelination in the maintenance of CNS integ-
rity. There is a large overlap in the clinical andMRI features
of MitCHAP-60, PMD, and PMLD,48 suggesting that the
HSPD1, PLP1, and GJA12 gene products, among others,
may comprise components of a common pathway, whose
disruption may lead to hypomyelination and SPG. Not-
withstanding the similarity of these MRI ﬁndings, there
are in fact signiﬁcant differences among the various hypo-
myelinating disorders. Of note is the fact that, as opposed
to PMLD patients affected by GJA12 mutations, in whom
some degree of myelination restricted to the corticospinal
tract can be identiﬁed by MRI,6 our MitCHAP-60 patients
exhibit complete absence of brain myelination. This differ-
ence in the extent of brainmyelin deﬁciency could explain
the relatively slow progression of spasticity in patient with
GJA12 defects, in contrast with the early and severeThe American Journal of Human Genetics 83, 30–42, July 2008 39
spasticity in MitCHAP-60 patients. Interestingly, PMD and
itsmilder variant spastic paraplegia 2 (SPG2 [MIM312920])
can serve as an example of allelic dysmyelinating disorders
sharing great similarity with our newly identiﬁed allelic
couple—MitCHAP-60 disease/SPG13.49 This phenotypic
resemblance between MitCHAP-60/SPG13 and PMD/
SPG2 allelic couples leads us to consider that common
pathogenicmechanismsmay contribute to these disorders.
In conclusion, we have identiﬁed a homozygous mis-
sense mutation (D29G), not previously described, in the
HSPD1 gene encoding the mitochondrial chaperonin
Hsp60 as the cause of a severe neurodegenerative disorder
herein termed MitCHAP-60 disease. This allows genetic
counseling and early prenatal diagnosis in a large consan-
guineous population in northern Israel. MitCHAP-60 is al-
lelic to SPG13, constituting a continuum of neurological
hypomyelinating syndromes with a wide spectrum of clin-
ical severity caused by a common genetic defect. Our work
has led to the inclusion of Hsp60 to the list of proteins in-
volved in myelinogenesis and further emphasizes the role
of chaperones in neurodegenerative disorders. It also con-
tributes to the evidence that mitochondrial integrity plays
a major part in a well-orchestrated myelinogenic program
and in the pathogenesis of neurodegenerative disorders.
Supplemental Data
A table containing genome-wide scan data using 50K-SNP-marker
microarray is available at http://www.ajhg.org/.
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